Targeting of mutant P53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy

Frontiers in Oncology

Volumn 6, Issue FEB, 2016, Pages

  Bykov, Vladimir J N ^a   Zhang, Qiang ^a   Zhang, Meiqiongzi ^a   Ceder, Sophia ^a   Abrahmsen, Lars ^b   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Aprea AB   (Sweden)

Author keywords

Apoptosis; APR 246; Cancer therapy; Clinical trial; Glutathione; Mutant p53; Redox balance; Thioredoxin reductase

Indexed keywords

ANTINEOPLASTIC AGENT; APR 246; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; IMATINIB; PLATINUM; PROTEIN P53; THIOREDOXIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL GROWTH; CELL VIABILITY; CHEMICAL STRUCTURE; DNA REPLICATION; GENE MUTATION; HUMAN; MISSENSE MUTATION; NONHUMAN; OXIDATION REDUCTION REACTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84964446349     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00021     Document Type: Review

References (47)

1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature (2013) 502(7471):333-9. doi: 10.1038/nature12634
2. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell (2009) 137(3):413-31. doi:10.1016/j.cell.2009.04.037
3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 126(1):107-20. doi:10.1016/j.cell.2006.05.036
4. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A (2010) 107(16):7455-60. doi:10.1073/pnas.1001006107
5. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A (2010) 107(16):7461-6. doi:10.1073/pnas.1002459107
6. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 14(5):359-70. doi:10.1038/nrc3711
7. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 149(6):1269-83. doi:10.1016/j.cell.2012.04.026
8. Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep (2013) 3(5):1339-45. doi:10.1016/j.celrep.2013.04.012
9. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science (2008) 319(5868):1352-5. doi:10.1126/science.1140735
10. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 12(4):303-12. doi:10.1016/j.ccr.2007.10.001
11. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 127(7):1323-34. doi:10.1016/j.cell.2006.12.007
12. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 445(7128):661-5. doi:10.1038/nature05541
13. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 445(7128):656-60. doi:10.1038/nature05529
14. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett (2014) 588(16):2622-7. doi:10.1016/j.febslet.2014.04.017
15. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 8(3):282-8. doi:10.1038/nm0302-282
16. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis (2002) 23(12):2011-8. doi:10.1093/carcin/23.12.2011
17. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 24(21):3484-91. doi:10.1038/sj.onc.1208419
18. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 15(5):376-88. doi:10.1016/j.ccr.2009.03.003
19. Kaar JL, Basse N, Joerger AC, Stephens E, Rutherford TJ, Fersht AR. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci (2010) 19(12):2267-78. doi:10.1002/pro.507
20. Sun XZ, Vinci C, Makmura L, Han S, Tran D, Nguyen J, et al. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal (2003) 5(5):655-65. doi:10.1089/152308603770310338
21. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 265(5170):346-55. doi:10.1126/science.8023157
22. Wassman CD, Baronio R, Demir O, Wallentine BD, Chen CK, Hall LV, et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun (2013) 4:1407. doi:10.1038/ncomms2361
23. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 41(12):6034-44. doi:10.1093/nar/gkt305
24. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget (2014) 5(19):8879-92. doi:10.18632/oncotarget.2432
25. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 113(Pt 10):1661-70
26. Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle (2007) 6(3):262-8. doi:10.4161/cc.6.3.3796
27. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene (2010) 29(49):6442-51. doi:10.1038/onc.2010.382
28. Shen J, van den Bogaard EH, Kouwenhoven EN, Bykov VJ, Rinne T, Zhang Q, et al. APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc Natl Acad Sci U S A (2013) 110(6):2157-62. doi:10.1073/pnas.1201993110
29. Shalom-Feuerstein R, Serror L, Aberdam E, Muller FJ, van Bokhoven H, Wiman KG, et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Proc Natl Acad Sci U S A (2013) 110(6):2152-6. doi:10.1073/pnas.1201753109
30. Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis (2013) 4:e881. doi:10.1038/cddis.2013.417
31. Mohell N, Alfredsson J, Fransson A, Uustalu M, Bystrom S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis (2015) 6:e1794. doi:10.1038/cddis.2015.143
32. Tessoulin B, Descamps G, Moreau P, Maiga S, Lode L, Godon C, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood (2014) 124(10):1626-36. doi:10.1182/blood-2014-01-548800
33. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 12(12):931-47. doi:10.1038/nrd4002
34. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 30(29):3633-9. doi:10.1200/JCO.2011.40.7783
35. Rieber M, Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem Pharmacol (2012) 84(12):1563-70. doi:10.1016/j.bcp.2012.09.003
36. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2007) 33(1):9-23. doi:10.1016/j.ctrv.2006.09.006
37. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res (2009) 15(24):7519-27. doi:10.1158/1078-0432.CCR-09-1068
38. Kobayashi N, Abedini M, Sakuragi N, Tsang BK. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Res (2013) 6:7. doi:10.1186/1757-2215-6-7
39. Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut (2015) 64(10):1506-16. doi:10.1136/gutjnl-2015-309770
40. Zahedi Avval F, Holmgren A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J Biol Chem (2009) 284(13):8233-40. doi:10.1074/jbc. M809338200
41. Ali D, Jonsson-Videsater K, Deneberg S, Bengtzen S, Nahi H, Paul C, et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol (2011) 86(3):206-15. doi:10.1111/j.1600-0609.2010.01557.x
42. Aguilar-Santelises M, Magnusson KP, Wiman KG, Mellstedt H, Jondal M. Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. Int J Cancer (1994) 58(4):474-9. doi:10.1002/ijc.2910580403
43. Zheng A, Castren K, Saily M, Savolainen ER, Koistinen P, Vahakangas K. p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer (1999) 79(3-4):407-15. doi:10.1038/sj.bjc.6690064
44. Cory AH, Chen J, Cory JG. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Anticancer Res (2006) 26(2A):1289-95
45. Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest New Drugs (2014) 32(5):783-94. doi:10.1007/s10637-014-0090-9
46. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res (2004) 64(16):5745-52. doi:10.1158/0008-5472.CAN-04-0195
47. Zandi R, Xu K, Poulsen HS, Roth JA, Ji L. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells. Cancer Invest (2011) 29(10):683-91. doi:10.3109/07357907.2011.626475